GHRP-6 Calculator

What Is GHRP-6?

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide composed of six amino acids (His-D-Trp-Ala-Trp-D-Phe-Lys). It belongs to the class of growth hormone secretagogues — compounds that stimulate the body's own release of growth hormone (GH) from the anterior pituitary gland. GHRP-6 is not a hormone itself; instead, it mimics the gut peptide ghrelin and triggers a natural, pulsatile release of GH. It was one of the first synthetic GHRPs to be characterized, dating to the 1980s, and it remains a reference molecule for research on the ghrelin axis.

Unlike recombinant growth hormone, which produces a constant, supraphysiological GH level, GHRP-6 works within the body's natural regulatory loops. The pituitary continues to release GH in pulses, and negative feedback through somatostatin and IGF-1 broadly remains intact. For this reason GHRP-6 is frequently used in preclinical research to study the dynamics of GH secretion without fully overriding the pituitary axis.

A defining feature of GHRP-6 — and the one that most clearly separates it from newer analogs such as ipamorelin — is its pronounced appetite stimulation. Because GHRP-6 is a direct ghrelin mimetic, and ghrelin is widely known as the "hunger hormone," it produces a marked increase in appetite in research models, often within 20 to 40 minutes of administration. Depending on the research objective this effect is either desirable or unwanted, and it should be considered when selecting the peptide. GHRP-6 is intended strictly for research purposes.

Mechanisms of Action

GHRP-6 exerts its effects primarily through the growth hormone secretagogue receptor (GHS-R1a), the same receptor that endogenous ghrelin binds. This gives rise to several interlocking effects:

• Ghrelin receptor (GHS-R1a) agonism: GHRP-6 binds GHS-R1a on somatotroph cells of the pituitary and in the hypothalamus. This binding activates the phospholipase C signaling pathway and raises intracellular calcium, which triggers the release of stored GH.
• Amplification of the GH pulse: GHRP-6 increases both the amplitude and the frequency of natural GH pulses. It acts synergistically with hypothalamic GHRH (growth hormone releasing hormone) and can partially blunt the inhibitory effect of somatostatin at the same time.
• Pronounced appetite stimulation: Through central ghrelin pathways in the hypothalamus — particularly the NPY/AgRP neurons of the arcuate nucleus — GHRP-6 produces a strong hunger signal. This is the clearest distinction from selective GHRPs such as ipamorelin and a reason GHRP-6 is studied in models of cachexia and appetite loss.
• Indirect IGF-1 elevation: The GH that is released stimulates the liver to produce IGF-1 (insulin-like growth factor 1). IGF-1 mediates much of the anabolic and regenerative activity associated with the GH axis.
• Possible effects on secondary axes: As a less selective GHRP, GHRP-6 can also influence prolactin and cortisol to varying degrees. These effects are generally smaller than with hexarelin but more pronounced than with the highly selective ipamorelin.

Dosage Calculation

GHRP-6 is usually administered in several small doses spread across the day, because the GH response is pulse-bound and the peptide's effect is short-lived. Ramping up gradually from a conservative starting dose is sensible in order to gauge individual tolerability, especially the appetite response.

Standard Dosing Parameters

• Conservative dose: 50–100 mcg (0.05–0.10 mg) per injection
• Standard dose: 100–150 mcg (0.10–0.15 mg) per injection
• Higher range: 200–300 mcg (0.20–0.30 mg) per injection
• Frequency: 2–3 times daily (for example, on waking, before training, and before sleep), each separated from carbohydrate- or fat-rich meals
• Half-life: approximately 2 hours, which is why dosing is split across the day
• Typical syringe: 0.3 mL insulin syringe (29–31 gauge, 6–8 mm needle)

Example Calculation: 5 mg Vial with 2 mL BAC Water

The most common vial size is 5 mg. Adding 2 mL of bacteriostatic water gives a concentration of 2.5 mg/mL (2,500 mcg/mL). The core formulas are: concentration = total mg ÷ BAC volume; volume per dose = target dose ÷ concentration.

• 100 mcg dose: 100 ÷ 2500 = 0.04 mL (4 units on a U100 syringe)
• 150 mcg dose: 150 ÷ 2500 = 0.06 mL (6 units)
• 200 mcg dose: 200 ÷ 2500 = 0.08 mL (8 units)
• 300 mcg dose: 300 ÷ 2500 = 0.12 mL (12 units)

At a typical daily schedule of 3 × 100 mcg (300 mcg total), a 5 mg vial lasts roughly 16 to 17 days. Use the GHRP-6 calculator above to compute exact volumes for any vial size, reconstitution volume, and target dose. The calculator also displays the matching IU scale of an insulin syringe.

Reconstitution

GHRP-6 is supplied as a lyophilized (freeze-dried) powder in sealed vials. It must be reconstituted with bacteriostatic water (BAC water) before use. Sterile water for injection should not be used for multi-dose vials because it lacks a preservative. BAC water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable window of the reconstituted solution.

Step-by-Step Reconstitution Protocol

1. Gather supplies: GHRP-6 vial, bacteriostatic water vial, alcohol swabs, a sterile draw needle (18–21 gauge), and your insulin syringe for injection.
2. Wipe the rubber septa of both vials with fresh alcohol swabs and allow them to air-dry for 30 seconds. Do not touch or blow on the septa afterward.
3. Draw the desired volume of BAC water (2 mL is standard for a 5 mg vial). A smaller volume raises the concentration and reduces the injection volume per dose.
4. Insert the needle into the GHRP-6 vial at an angle so the tip points toward the inner glass wall rather than directly at the lyophilized powder. A direct stream onto the powder cake can create shear forces and damage the peptide.
5. Push the plunger slowly, letting the BAC water run down the inside glass wall and gently wet the powder from below.
6. Gently roll or swirl the vial between your palms until the powder is fully dissolved. The solution should appear clear and colorless. Do not shake or vortex, as foam and shear stress strain the peptide.
7. Label the vial with the reconstitution date and concentration (e.g., "GHRP-6 2.5 mg/mL, reconstituted [date]").

If the solution appears cloudy, discolored, or contains visible particulate matter, discard the vial and do not use it.

Storage and Shelf Life

• Lyophilized powder (unreconstituted): Store at −20°C for long-term storage, where the powder is stable for 24+ months. Short-term storage at 2–8°C in a refrigerator is acceptable for a few weeks. Protect from light and moisture.
• Reconstituted solution: Store in the refrigerator at 2–8°C. GHRP-6 in solution is typically stable for about 2–3 weeks. Keep the vial upright, away from light, and with the reconstitution date clearly visible.
• Do not freeze reconstituted peptide. Freeze-thaw cycles promote peptide aggregation and loss of activity. The dissolved solution should remain refrigerated throughout its use window.
• Transport: Use an insulated cooler with an ice pack for any travel lasting more than 1–2 hours. Avoid exposure to temperatures above 25°C during transport.

Side Effects and Safety Profile

GHRP-6 is well characterized in preclinical research and is considered comparatively well tolerated at moderate doses. Because robust long-term human clinical data is lacking, all use remains in the research domain. The observations below come primarily from preclinical models and reports from the research community.

Commonly Reported Observations

• Strong hunger: The best-known effect of GHRP-6. A pronounced increase in appetite often appears within 20–40 minutes of administration. Depending on the research objective, this is either welcome or disruptive.
• Mild redness, transient swelling, or brief discomfort at the injection site. Rotating injection sites reduces localized irritation.
• Tingling, warmth, or a feeling of tightness in the hands, attributed to a temporary fluid shift in tissue (water retention).
• Brief lightheadedness or a mild drop in blood pressure immediately after injection, particularly at higher doses.

Less Common or Theoretical Concerns

• Cortisol and prolactin elevation: At high doses, GHRP-6 as a less selective GHRP can mildly raise cortisol and prolactin. Low to moderate doses generally keep this effect small.
• Effect on blood glucose: GH secretagogues can transiently alter insulin sensitivity. Research in models with impaired glucose metabolism should account for this.
• Receptor desensitization: Sustained high dosing over long periods could theoretically blunt the GHS-R1a response. For this reason, cyclical protocols with breaks are discussed.

Contraindications

• Active cancer or a history of malignancy, as the GH/IGF-1 axis promotes cell growth
• Pregnancy and breastfeeding, due to insufficient safety data
• Diabetic retinopathy or severely uncontrolled glucose metabolism
• Known hypersensitivity to any component of the preparation

No serious adverse events have been attributed to GHRP-6 in the published research at moderate doses. Given the absence of large-scale human trials, caution is warranted, and consultation with a qualified healthcare professional is strongly recommended.

Combinations and Stacks

GHRP-6 + CJC-1295 — The GHRH and GHRP Synergy

The most widely described combination pairs GHRP-6 with a GHRH analog such as CJC-1295 (no DAC). The two peptides act at different points of the GH axis and therefore complement one another: a GHRH analog increases the amount of GH that can be released per pulse, while GHRP-6 provides the trigger for the pulse itself and simultaneously dampens the inhibitory action of somatostatin. In research models, co-administration produces a GH response greater than the sum of the individual effects. When both peptides are given at the same time, the GH pulses can be synchronized.

Comparison Within the GHRP Class

Within the GHRP family, GHRP-6 is distinguished mainly by its side-effect profile. Ipamorelin is considered the most selective GHRP, with little effect on appetite, cortisol, and prolactin, and is often chosen when appetite stimulation is unwanted. GHRP-2 sits in between, with a moderate appetite effect and a slightly stronger GH surge. Hexarelin is the most potent classic GHRP but is the most prone to receptor desensitization. GHRP-6 is selected mainly when its pronounced appetite effect is part of the research objective.

Note on Stack Administration

Although GHRP-6 and a GHRH analog are often administered close together in time, each peptide should be reconstituted separately. Mixing them in a single syringe is possible, but their combined stability in solution is not well characterized. Separate injections at adjacent sites eliminate dosing errors and possible interactions. Standalone GHRP-6 use is also common when the research focus is solely the ghrelin axis or appetite regulation.

Frequently Asked Questions

How does GHRP-6 differ from ipamorelin?

The most important difference is selectivity. Ipamorelin is a highly selective pentapeptide that releases GH without meaningfully increasing appetite and with minimal effect on cortisol and prolactin. GHRP-6 is a more direct ghrelin mimetic and causes a marked rise in appetite along with potentially stronger effects on secondary axes. If appetite stimulation is desired, GHRP-6 is preferred; if it should be avoided, ipamorelin is the natural choice.

Why is GHRP-6 administered several times a day?

GHRP-6 has a short half-life of roughly two hours and triggers a pulsatile, time-limited release of GH. A single daily dose would produce only one pulse. Research protocols therefore usually split the dose across two or three smaller administrations during the day in order to trigger multiple GH pulses.

Should GHRP-6 be administered around meals?

Research models observe that a carbohydrate- or fat-rich meal shortly before or after administration can blunt the GH response. For this reason, a gap of about 20–30 minutes from such meals is often chosen. Administration on an empty stomach is regarded as the most favorable condition for a pronounced GH release.

Does GHRP-6 always cause intense hunger?

A noticeable appetite stimulation is the most characteristic effect of GHRP-6 because it is a direct ghrelin mimetic. The intensity is dose-dependent and varies between individuals. Some users report that the effect lessens somewhat with continued use. Anyone who wants to avoid an increase in appetite typically chooses a more selective GHRP such as ipamorelin.

Does GHRP-6 affect the body's own GH production?

GHRP-6 works within the body's natural regulatory loops and does not suppress endogenous GH production in the way exogenous, recombinant growth hormone does. The pituitary continues to release GH in pulses. Feedback mechanisms via IGF-1 and somatostatin nonetheless remain active, and cyclical protocols with breaks are discussed as a precaution given the lack of long-term human data.

How long does a typical GHRP-6 research cycle last?

In research discussion, cycles of 8 to 12 weeks followed by breaks are common. The breaks are intended to guard against a possible blunting of the GHS-R1a response. Specific durations depend on the model and research question and do not constitute a recommendation for use in humans.

Is GHRP-6 detectable in sports drug testing?

GHRP-6 is classified under the WADA prohibited list among banned GH secretagogues and peptide hormones. Specialized detection assays for GHRPs exist. Athletes subject to WADA-compliant testing should treat GHRP-6 as a prohibited substance and always verify the anti-doping rules currently in force.

Where can I buy GHRP-6?

GHRP-6 is strictly a research compound. For an overview of the available peptides and their calculators, see the peptide calculator hub. All compounds listed at BergdorfBio are offered strictly for research purposes.

Medical Disclaimer: The information on this page is provided for educational and research purposes only. GHRP-6 is not an approved drug or medical treatment and is provided strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. The regulatory status of peptides varies by jurisdiction. BergdorfBio assumes no liability for the use or misuse of the information presented here.